Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A N Hughes

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Lancet. Oncology|March 22, 2002
Pemetrexed disodium, a novel antifolate with multiple targetsN J Curtin, A N Hughes
Physical Review Letters|April 6, 2001
Direct measurement of a pure rotation transition in H2(+)A D Critchley, A N Hughes, I R McNab
British Journal of Cancer|May 2, 2000
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxelA N Hughes, M J Griffin, D R Newell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 daysA N Hughes, I Rafi, M J Griffin, et al.
British Journal of Cancer|March 10, 2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigationsA Azzabi, A N Hughes, P M Calvert, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Lancet. Oncology|March 22, 2002
Pemetrexed disodium, a novel antifolate with multiple targetsN J Curtin, A N Hughes
Physical Review Letters|April 6, 2001
Direct measurement of a pure rotation transition in H2(+)A D Critchley, A N Hughes, I R McNab
British Journal of Cancer|May 2, 2000
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxelA N Hughes, M J Griffin, D R Newell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 daysA N Hughes, I Rafi, M J Griffin, et al.
British Journal of Cancer|March 10, 2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigationsA Azzabi, A N Hughes, P M Calvert, et al.
Pageof 1